Accelerated ART Initiation for PWHIV Who Are Out of Care
Conditions: HIV Infections; ART; Noncompliance, Patient Interventions: Other: The Accelerate model of care; Drug: bictegravir/emtricitabine/tenofovir alafenamide 50/200/25 mg Sponsors: University of Missouri-Columbia; Gilead Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Tenofovir Disoproxil Fumarate in the Treatment of Parkinson's Disease
Conditions: Parkinson Disease Interventions: Drug: Tenofovir Disoproxil Fumarate Sponsors: The Fourth Affiliated Hospital of Zhejiang University School of Medicine Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 10, 2024 Category: Research Source Type: clinical trials
From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients
Conditions: Chronic Hepatitis b Interventions: Drug: Terbinafine; Drug: Placebo; Drug: Tenofovir Sponsors: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 6, 2024 Category: Research Source Type: clinical trials
Dapivirine Vaginal Ring and Oral Pre-Exposure Prophylaxis Found Safe for HIV Prevention Throughout Pregnancy
March 5, 2024 -- The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 5, 2024 Category: Pharmaceuticals Source Type: clinical trials
Single Ascending Dose, Food Effects and Drug-Drug Interactions of ACC017 Tablets in Healthy Adult Participants
Conditions: Healthy Adult Participants Interventions: Drug: ACC017 tablets; Drug: Emtricitabine and Tenofovir Alafenamide Fumarate Tablets Sponsors: Jiangsu Aidea Pharmaceutical Co., Ltd; Chengdu Aidea Pharmaceutical Technology Co., Ltd Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
Impact of Long-acting Injectable Cabotegravir for HIV PrEP in MSM in France.
Conditions: Prevention Interventions: Drug: Cabotegravir Tablets, for oral use.; Drug: Cabotegravir Extended-Release Injectable Suspension, for intramuscular use.; Drug: Tenofovir disoproxil/Emtricitabine 300mg/200mg fixed-dose combination tablets, for oral use; Procedure: Rectal Biopsies Sponsors: ANRS, Emerging Infectious Diseases Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 23, 2024 Category: Research Source Type: clinical trials
Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT
Conditions: HIV Infections Interventions: Drug: APRETUDE (cabotegravir) 600 mg\3 mL; Drug: DAPIRING (Dapivirine) 25mg Vaginal Ring; Drug: tenofovir disoproxil and emtricitabine; Drug: Tenofovir Disoproxil, Lamuvidine and Dolutegravir Sponsors: Africa Health Research Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Clinical Trial for Non-inferiority and Safety of Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate in Patients With Hematologic Malignancies Who Require Prophylactic Hepatitis B Antiviral Treatment
Conditions: Patients With Malignant Blood Disease Requiring Hepatitis B Antiviral Medication Interventions: Drug: Vemlidy; Drug: Virreal Sponsors: Yonsei University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials
DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-na ïve People Living With HIV-1 Infection
Conditions: HIV-1-infection Interventions: Drug: Doravirine + tenofovir DF + lamivudine; Drug: Dolutegravir + tenofovir DF + lamivudine or emtricitabine Sponsors: ANRS, Emerging Infectious Diseases; MSD France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Entecavir versus tenofovir for prevention of hepatitis B virus-associated hepatocellular carcinoma after curative resection: study protocol for a randomized, open-label trial
This study is a randomized, open-label trial. A total of 240 participants will be randomized 1:1 into groups receiving TDF or entecavir monotherapy. The two groups will be compared in terms of recurrence-free and overall survival at 1, 3, and 5 years after surgery; adverse events; virological response; rate of alanine transaminase normalization; and seroreactivity at 24 and 48 weeks after surgery.DiscussionThis study will compare long-term survival between patients with HBV-associated HCC who receive TDF or entecavir monotherapy. Numerous outcomes related to prognosis will be analyzed and compared in this study.Trial re...
Source: Trials - January 5, 2024 Category: Research Source Type: clinical trials
Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected na ïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)
Conditions: HIV Infections Interventions: Drug: BIC/FTC/TAF Sponsors: Carmen Hidalgo Tenorio; Gilead Sciences Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 20, 2023 Category: Research Source Type: clinical trials
The effect of switch therapy to tenofovir versus entecavir maintenance on recurrence of hepatocellular carcinoma after surgery (SWITE): study protocol for a randomized controlled trial
AbstractBackgroundAntiviral therapy has been reported to be associated with lower recurrence rate of hepatocellular carcinoma (HCC) for patients with hepatitis B virus (HBV) infection. While entecavir (ETV) and tenofovir disoproxil fumarate (TDF) were both recommended as first-line therapies for HBV patients, recent retrospective studies proposed a lower incidence rate of HCC occurrence or recurrence in those receiving TDF compared ETV. However, the survival benefits of switching to TDF therapy after prolonged ETV treatment before surgery remain uncertain. We delineate the rationale and design of SWITE, a randomized, open-...
Source: Trials - December 2, 2023 Category: Research Source Type: clinical trials
A Clinical Study of TQA3605 Tablets Monotherapy or in Combination With Nucleoside (Acid) Analogues in Treatment Naive and Treated Patients With Chronic Hepatitis B
Conditions: Chronic Hepatitis b Interventions: Drug: Placebo; Drug: TQA3605 tablets; Drug: Entecavir dispersible tablets; Drug: Tenofovir disoproxil fumarate tablet; Drug: Tenofovir alafenamide fumarate tablet Sponsors: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 29, 2023 Category: Research Source Type: clinical trials
Acceptability and Feasibility of Injectable Cabotegravir Pre-exposure Prophylaxis (PrEP) Versus Oral PrEP in Routine Care up to 15 Months in Private Pharmacies in South Africa
Conditions: HIV Infections Interventions: Drug: Cabotegravir Injection [Apretude]; Drug: Tenofovir disoproxil fumarate / emtricitabine (or lamivudine) Sponsors: University of Witwatersrand, South Africa; ViiV Healthcare; Bill and Melinda Gates Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 18, 2023 Category: Research Source Type: clinical trials
Implementing Oral (Event-driven and Daily) and Long-acting Pre-Exposure Prophylaxis in Mobile Men in Sub-Saharan Africa
Conditions: HIV Interventions: Drug: Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC), cabotegravir (CAB-LA); Drug: Cabotegravir (CAB-LA), Tenofovir disoproxil fumarate/emtricitabine (TDF-FTC) Sponsors: MRC/UVRI and LSHTM Uganda Research Unit; King ' s College London; London School of Hygiene and Tropical Medicine; Africa Health Research Institute; Wits Health Consortium (Pty) Ltd; University College, London; Ministry of Health, Uganda; Desmond Tutu HIV Foundation; Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2023 Category: Research Source Type: clinical trials
